Rocket Pharmaceuticals (RCKT) Research & Development (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Research & Development data on file, last reported at $31.5 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 12.49% year-over-year to $31.5 million; the trailing twelve-month figure through Mar 2026 stood at $137.5 million (down 15.09% YoY), and the FY2025 full-year result was $142.0 million, down 17.07% from the prior year.
• Research & Development climbed to $31.5 million in Q1 2026, from $29.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $51.4 million in Q2 2023 to a low of $29.3 million in Q4 2025.
• A 5-year average of $41.0 million and a median of $42.3 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 68.59% in 2022 and dropped 21.44% in 2025, its largest moves.
• Tracing RCKT's Research & Development over 5 years: stood at $50.0 million in 2022, then fell by 16.57% to $41.7 million in 2023, then dropped by 10.51% to $37.4 million in 2024, then retreated by 21.44% to $29.3 million in 2025, then gained by 7.18% to $31.5 million in 2026.
• Business Quant data shows RCKT's Research & Development at $31.5 million in Q1 2026, $29.3 million in Q4 2025, and $34.1 million in Q3 2025.